Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 1Rectal Neoplasms 1Liver Neoplasms 1Hematologic Neoplasms 1Esophageal Neoplasms 1Colonic Neoplasms 1Brain Neoplasms 1

Interventions

Oxaliplatin 21pembrolizumab 17Capecitabine 15Nivolumab 13Paclitaxel 12Fluorouracil 12Leucovorin 11Docetaxel 10atezolizumab 7Trastuzumab 7tislelizumab 5Ramucirumab 5durvalumab 4Standard of Care 4Magnetic Resonance Spectroscopy 4Irinotecan 4Cisplatin 4Carboplatin 4zolbetuximab 3zimberelimab 3apatinib 3Specimen Handling 3S 1 (combination) 3Gemcitabine 3Bevacizumab 3trifluridine tipiracil drug combination 2tremelimumab 2trastuzumab deruxtecan 2relatlimab 2osimertinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Stomach Neoplasms × ropidoxuridine × Clear all
NCT02381561 2026-04-13

Ropidoxuridine in Treating Patients With Advanced Gastrointestinal Cancer Undergoing Radiation Therapy

National Cancer Institute (NCI)

Phase 1 Active not recruiting
19 enrolled
Gastrointestinal

Colonic Neoplasms, Esophageal Neoplasms, Liver Neoplasms, Rectal Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡